CompletedPhase 4

Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg

South Korea379 participantsStarted 2019-01-29

Plain-language summary

To Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Male or Female aged ≥ 19 years
✓. Episode of heartburn for 3 months or more during prior to randomization visit.
✓. Episode of heartburn for 2 days or more during the last 7 days prior to randomization visit.
✓. Grade N, M by EGD test.

Complete resolution of heartburn(HB), Last 7 days of treatment, 4 weeks.

Timeframe: 4 weeks after drug administrations.

NCT IDNCT03928470

SponsorChong Kun Dang Pharmaceutical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-12-20